It is controversial whether ovarian epithelial carcinoma possesses steroidogenic enzymes. We investigated aromatase expression in ovarian epithelial carcinoma, and compared it with the normal ovary and placenta. Samples were obtained from an ovarian carcinoma cell line SK-OV-3, ovarian tumour tissues from four patients with epithelial carcinoma and one patient with dysgerminoma. Aromatase enzymatic activity was measured in microsome fractions by quantitating 3H 2 0 released from [1-3H] androstenedione and [3H] oestrone converted from [1,2,6,7-3H] androstenedione. Aromatase messenger ribonucleic acid (mRNA) was determined by reverse transcription-polymerase chain reaction (RT-PCR) using oligonucleotide primers synthesized according to the published human aromatase gene sequence.
SUMMARY. It is controversial whether ovarian epithelial carcinoma possesses steroidogenic enzymes. We investigated aromatase expression in ovarian epithelial carcinoma, and compared it with the normal ovary and placenta. Samples were obtained from an ovarian carcinoma cell line SK-OV-3, ovarian tumour tissues from four patients with epithelial carcinoma and one patient with dysgerminoma. Aromatase enzymatic activity was measured in microsome fractions by quantitating 3H 2 0 released from [1-3H] androstenedione and [3H] oestrone converted from [1,2,6,7-3H] androstenedione. Aromatase messenger ribonucleic acid (mRNA) was determined by reverse transcription-polymerase chain reaction (RT-PCR) using oligonucleotide primers synthesized according to the published human aromatase gene sequence.
No aromatase activity was detected in either of two mucinous cystadenocarcinoma specimens or in SK-OV-3 cells, while aromatization proceeded with apparent Michaelis-Menten kinetics in the normal ovaries and placentas. The apparent Km value was 200 nmollL for the ovary. Aromatase mRNA was detected in dysgerminoma, and the normal ovary and placenta, but not in any of three mucinous cystadenocarcinoma specimens, one serous cystadenocarcinoma specimen and SK-OV-3 cells. These results for both enzyme activity and gene expression suggest that the human ovarian epithelial carcinoma lacks aromatase. The demonstration of absence of aromatase gene expression raises the possibility that aromatase activity in ovaries bearing epithelial carcinoma may be associated with hyperplastic stromal rather than tumour cells.
Additional key phrases: oestrogens; mRNA; ovary; placenta It remains poorly understood whether ovarian epithelial carcinoma is an endocrine or nonendocrine tissue. Some postmenopausal patients with this disease reveal above normal level of circulating oestrogen.l-' and in that case ovarian venous blood contains increased sex steroid when compared to those in women with normal ovaries.v' The level of plasma concentration of sex steroid has been demonstrated to correlate with the volume of malignant epithelial tissue in the abdomen.v' Such circumstantial evidence suggests the presence at least of oestrogen synthesis by the ovaries bearing malignant epithelial tumour. Recent in vitro studies have presented data which demonstrated: (i) an excessive androstenedione production with a Correspondence: Dr A Imai, subsequent production of oestrogen in ovarian carcinoma tissue:" and (ii) aromatase activity in human ovarian carcinoma microsomes" and in epithelial tumour cells cultured from patients with ovarian carcinoma." However, it is generally argued that steroid produced by the normal ovary is a product of stromal rather than epithelial cells. No previous reports have determined whether the aromatase in the tumour-bearing ovary was associated with carcinoma cells, hyperplastic stromal tissue, or surrounding connective tissue. It is, therefore, of interest to determine whether aromatase activity and messenger ribonucleic acid (mRNA) are expressed in the epithelial tumour tissues from patients with ovarian carcinoma. In this study, we have examined various ovarian epithelial carcinomas and an ovarian carcinoma cell line for the presence of aromatase enzyme and messenger ribonucleic acid.
MATERIALS AND METHODS

Cell cultures
Human ovarian adenocarcinoma cell line SK-OV-3 was obtained from the American Type Culture Collection. The cells were grown at 37 D C in an appropriate medium containing 100/0 fetal bovine serum in 150 mL flasks in a humidified atmosphere of 5% CO 2 -95 % air. For the experiments with oestrone (E I ) and oestradiol 17{:j (E2)' the steroids were added as dimethyl sulphoxide (M~SO) solution; Me2S0 concentrations in the medium were less than O·01%. All tissue culture media also contained penicillin (100 U/mL), streptomycin (100 /Lg/mL) and neomycin (100 /Lg/mL).
Tissue collection
Ovarian tumours and normal tissue were placed on ice-cold phosphate-buffered saline (PBS) immediately after surgical removal and representative portions were excised to prepare the material for histological frozen sections. We attempted to isolate carefully normal tissue or stroma of tumour-bearing ovaries from the tumour tissue. As our preliminary experiments showed the aromatase activity/expression to be in the stromal tissues of the ovary bearing carcinoma, carcinoma samples were subsequently prepared from a firm polypoid mass growing from the tumour. These tissue samples were washed well with PBS, and immediately used or stored in liquid nitrogen.
Preparation of microsome fractions
Each tissue fragment (-2 g) or cell pellet (-5 X 10 7 cells) was homogenized at ODC in a total of 10 mL homogenizing buffer (100 mmollL Tris, 1 mmollL ethylenediamine tetraacetic acid (EDTA), 1 mmollL dithiothreitol, pH 7-4) using a teflon homogenizer. 8 The homogenate was centrifuged at 1000 x g at 4 DC for 10 min, and the resultant supernatant was centrifuged again at 100 000 x g for 1 h. The pellets were suspended in phosphate buffer (10 mmollL KC1, 1 mmollL EDTA, lOmmol/L KH 2P04 , pH 7'4) and used as membrane (microsome) preparations. Marker enzyme analysis was performed using 5' -nucleotidase as a marker for the microsomecontaining plasma membrane." Protein concentrations were determined by a standard Ann Clin Biochem 1994: 31 procedure'? with bovine serum albumin as the reference. The specific activity was increased threefold from I . 5 to 4· 5 /Lmollmg protein/h in the microsome fraction, when compared to the homogenate.
Assay of aromatase activity
The aromatase activity was measured as the stereospecific loss of hydrogen from exogenously supplied [1{:j-3H] androstenedione, and also its incorporation into 3H 20.II,12 Routinely, membrane fractions were incubated with a saturating concentration of PH] androstenedione in an NADPH-generating system.
The reaction mixture consisted of the membrane preparations (1-100 /Lg protein), 10 mmollL glucose 6-phosphate, two units glucose 6-phosphate dehydrogenase, 1 mmollL NADP + , various concentrations of [l{PH] androstenedione (about lOS dpm/nmol), 0·1 mollL phosphate buffer (pH 7· 5) in a total volume of O' 1 mL. For the studies of steroid effects, the agents were dissolved in Me2S0; Me2S0 concentrations in the incubations were less than O' 1%. After desired intervals the reactions were terminated with O' 5 mL of chloroform: methanol (I :2, v/v) followed by 0'1 mL chloroform and 0'1 mL H 20. The 3H 20 generated, contained in the water layer, was counted. The assay recovery was determined from a set of tubes containing 3H 20; recovery was 85 to 90%. The concentration of the substrate remained relatively unchanged during the course of the determination.
In some experiments to validate the use of the assay to determine aromatase activity of our membrane fractions, comparisons of 3H 20 production to authentic product formed were made using [1_ 3H]and [1,2,6, 7-3H] -androstenedione. With [1,2,6,7.3H] androstenedione used as substrate, the extracted steroids in the chloroform layer were separated by thin layer chromatography. 13 Areas with E 1 and E 2 , expected steroid products of aromatase activity of these membrane fractions, were counted. Only E I production was noted, and the production rate was found not to differ from 3H 20 production rate using the same membrane preparation. We concluded that determination of incorporation of radioactivity into 3H 20 is a valid assay of the aromatase activity of membrane fractions prepared under our condition. The lower limits of sensitivity of the assay ranged from 0'01 to 0'02pmollmg protein/h.
Ribonucleic acid (RNA) isolation
Total RNA was extracted from tissues or from cell pellets according to the procedure of Chromcynski and Sacchi." Briefly, the specimens were homogenized in guanidium thiocyanate followed by acid phenol/chloroform extraction, precipitated with isopropanol and reextracted with guanidium thiocyanate and isopropanol precipitation. Poly(A) mRNA was then prepared using oligo(dT) cellulose column, IS according to the manufacturer's instructions.
Reverse transcription and polymerase chain reaction amplification A random primed complementary deoxyribonucleic acid (cDNA) library was prepared from 200 ng of poly(A) RNA with the Moloney murine leukaemia reverse transcriptase according to the manufacturer's recommendation. The cDNA reaction (25 ILL) was diluted into 300 ILL water, heat-denatured at 95°C for 5 min, and quickly chilled on ice.
The cDNA (I ILL) was amplified in a 50 ILL reaction containing 10 mmol/L Tris-HCI (pH 8·3), 50 mmol/L KCI, 2 mmol/L MgCI 2, 50 ILmol/L each deoxynucleoside triphosphates (dNTP), and 1·25 units Taq polymerase, and 0·5 ILmol/L primers;" The sequences of oligonucleotide primers, synthesized according to the published human aromatase sequence, 17,18 were as follows: primer I (5' -+ 3 I , 348 to 369, ACTACTACAACCGGGTATATGG); primer II (5 I -+ 3 I , 749 to 769, AACCACGAT-AGCACTTTCGTC). The predicted fragment amplified by PCR was 422 base pairs. We carried out 35 cycles of amplification; denaturation at 94°C for 2 min, annealing at 55°C for 1 min, and extension at noc for 2 min followed by a final extension for 10 min at noc. The DNA product (10 ILL) was run on 2% agarose gels, and bands were visualized by ethidium bromide staining on an ultra-violet transilluminator.
Restriction enzyme analysis Polymerase chain reaction (PCR) products were digested with restriction endonuclease enzymes
Eco T22 I or Sac I under the conditions recommended by the supplier. The digests along with the untreated aliquots of each PCR sample were then fractionated by electrophoresis in 2070 agarose gels, and stained.
Sequence analysis Sequence analysis of the PCR products were performed manually using a Sequencenase kit,19
Aromatase mRNA in ovarian carcinoma 67 after elution into 0·5 mol/L ammonium acetate, 1 mmol/L EDTA, and O·1% sodium dodecyl sulphate followed by ethanol precipitation. 5 I -End labelled 32P-oligonucleotides were used as primers for the sequence analysis. 
Materials
RESULTS
Lack of aromatase activity in ovarian carcinoma
The aromatase activity was examined in membrane fractions from three different mucinous cystadenocarcinoma tissues, an ovarian carcinoma cell line SK-OV-3, two different full-term placenta tissues, and two different normal ovaries. In contrast to the placentas or normal ovaries, in which the aromatase activity was significantly detected, there was no detectable aromatase activity in any of the three membrane fractions prepared from ovarian carcinomas and SK-OV-3 ( Fig. Ib) . In membrane fractions from the placenta or the normal ovary, aromatization proceeded in a linear manner as a function of incubation time for up to 60 min ( Fig. la) , as a function of the membrane protein concentration (Fig. 2a ), and as a function of the androstenedione concentration ( Fig. 3 ). By double reciprocal plots, the apparent Km of the ovarian membrane enzyme was computed to be 200 nmol/L (Fig. 3) , similar to the value previously reported for aromatase of whole ovarian tissue. Exogenously added 10 nmol/L E 1 and E 2 caused 90070-and 50%-inhibition, respectively, of aromatase activity associated with ovarian membrane as shown in Fig. 2a . On the other hand, no significant aromatase activity was detected in membrane fractions from ovarian carcinoma or SK-QV-3, even after 60 min of incubation ( Fig. la) , at concentrations of Lack of aromatase mRNA in ovarian carcinoma PCR amplification of first-strand cDNA from human ovarian tumours, SK-OV-3, the placenta and the normal ovary were conducted with a set of oligonucleotide primers as designed according to the established aromatase gene (Fig. 4) . The placenta and the normal ovary yielded the expected 422-base pair products, while no detectable products were obtained in any of the four ovarian carcinomas (three mucinous cystadenocarcinoma and one serous cystadenocarcinoma) and SK-OV-3. Of the ovarian tumours, dysgerminoma gave a predominant product identical to that obtained in the placenta or the normal ovary. Incubation of SK-OV-3 with E 1 or E 2 for 48 h did not cause any expression of aromatase (data not shown).
The PCR product yielded in the ovary was then confirmed to be identical to that of aromatase gene. The predicted sequences of DNA products generated by the set of aromatase primers membrane protein up to 2·7 mg (Fig. 2b) , and at concentrations of substrate androstenedione up to 200 nmollL (Fig. 3 ). E 1 and E 2 did not influence the aromatization rate . Figure 5 shows that digestion of the products produced fragments of the expected sizes. By sequence analysis, the product was also Aromatase mRNA in ovarian carcinoma 69 observed to have homology to the consensus sequence (data not shown).
DISCUSSION
Oestrogens may be the predominant mitogenic factors required for the growth of hormonedependent tumours in both men and women. Therefore, it is possible that intra-tumoural oestrogen could function as an autocrine or paracrine growth factor and impart a growth advantage to carcinoma cells that synthesize their own mitogenic signal. In a recent study that used an enzymatic assay, significant intratumoural aromatase activity has been found in human breast carcinomas,20.21 ovarian epithelial carcinoma,6. 7 choriocarcinoma.P and prostatic carcinomas;" Although it remains unclear whether these tumours possess sufficient aromatase activity to affect peripheral oestrogen levels, the presence of intra-tumoural aromatase can lead to local synthesis of oestrogen in these tumours. To extend these observations in some important aspects, in particular to demonstrate whether the tumour aromatase enzymatic activity is associated with carcinoma cells, surrounding stromal or connective tissue, and whether the tumour cells express aromatase mRNA, we have analysed for the first time the aromatase gene expression in human ovarian epithelial carcinomas. The present study demonstrates the absence both of significant aromatase activity and an aromatase mRNA in all ovarian epithelial carcinomas tested, while the normal ovary and dysgerminoma were observed to express aromatase. Although care was taken to avoid use of damaged tissue, the possibility that lack of aromatase could have been due to loss of enzyme activity and RNA denaturation during procurement of some samples cannot be excluded. However,S' -nucleotidase activity, marker enzyme of microsome-containing plasma membrane (see Experimental Procedure), and gonadotropin-releasing hormone mRNA expression" have been maintained under our experimental system. Despite any potential limitations caused by the condition of the tissue, our findings strongly suggest that results obtained by the gene expression and enzyme activity assay are consistent with the presence of aromatase in ovarian carcinoma.
The results of a lack of aromatase in ovarian carcinoma contrast with previous reports in ovarian epithelial carcinoma, which measured aromatase activity using 3H 2 0 assay in microsome fractions" or E 2 production by radioimmunoassay in epithelial tumour cells cultured from patients with ovarian carcinoma." One possible explanation for this discrepancy is that 3H 2 0 released from radiolabelled androgen may not always correlate with aromatase activity and may be, at least in part, the result of other metabolic reactions, as recently indicated by Brodie et al. 25 Another possibility is that relatively large amounts of intra-tumoural oestrogen may be synthesized by the sulphatase pathway. 26 In fact, apparent Km values (micromolar) in ovarian carcinoma aromatase reported by others? were much higher than those of other tissues such as placenta," brain 28 and ovarian granulosa cell,29 where they were reported in the nanomolar range as we confirmed. The demonstration of absence of aromatase in hormone-sensitive tumour is not without precedent since the enzyme has been reported to be absent from prostatic carcinomas known to have increased intra-tumoural oestrogen production and to be affected by oestrogen.P Peripheral aromatization increases with age in men and women. Loubet et al. 30 in their review of ovarian stroma after the menopause hypothesized that cessation of follicular development and persistence of functional stroma might be correlated with changes in the vascular component, which preserved blood flow preferentially to the stroma. Stroma of postmenopausal ovaries are not quiescent, and most reports have agreed that androgen, not oestrogen, was the secretory product. 31 Judd 32 measured androgen concentrations in postmenopausal ovarian venous blood and concluded that menopause was associated with an increase in androgen secretion. Taking these findings together with ours, the oestrogen synthesis by ovaries bearing malignant epithelial tumours may result from androgen production in hyperplastic stromal cells, but not in tumour cells.
The authenticity of the aromatase we observed and its production by the normal ovary, placenta and dysgerminoma was further established by the demonstration of aromatase mRNA by PCR amplification study in these tissues. This demonstration was based on the generation of identical PCR amplification products in reverse transcription (RT) RNA from the placenta, as well established site of aromatase presence. The amplification products had the predicted sizes, and included complementary sequences for aromatase probes, and restriction enzymes fragments had the predicted sizes. The sizes of the Ann C/in Biochem 1994: 31 amplification products excluded the possibility that they could have resulted from amplification of genomic DNA. The possibility that our results might be accounted for by cross-tissue contamination, the ovary bearing carcinoma and the carcinoma, seemed highly unlikely, since no RT-PCR products were detected when the aromatase primers were used with ovarian carcinoma and SK-OV-3 and since RT and PCR blanks always remained negative. Under these conditions of RT-PCR amplification and amplification product analysis we showed that amplified sequences of the aromatase cDNA were generated from human ovary mRNA.
In conclusion, the lack of aromatase in ovarian carcinoma tissue suggests that an involvement of ovarian tumour cell aromatase in oestrogen production is unlikely, and the stroma cell may more likely play a major role. The possible control of ovarian carcinoma growth in a paracrine manner raises intriguing questions: (i) does ovarian epithelial tumour stimulate the stromal hyperplasia? and (ii) can an aberrant stroma provoke development of the tumour cells through oestrogen? Answers to these questions would prove whether sequential use of aromatase inhibitors may be of value in extending the disease-free interval in ovarian carcinoma patients, as in the case of breast cancer.
